Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03463161
Title Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy (ORKA)
Acronym ORKA
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Chicago
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.